Discontinuing Anticoagulation in Atrial Fibrillation Dramatically Increases Stroke Risk
Stopping anticoagulation in patients with atrial fibrillation increases the risk of ischemic stroke by 2-3 fold, with the highest risk occurring within 2-3 months of discontinuation. This elevated risk persists regardless of whether the patient was on warfarin or a direct oral anticoagulant (DOAC), and applies to all patterns of AF—paroxysmal, persistent, or permanent 1, 2.
Magnitude of Risk After Discontinuation
The evidence consistently demonstrates substantial harm from anticoagulation interruption:
- 2-3 fold increased stroke risk when anticoagulation is discontinued versus continued 2, 3
- Highest risk period: 2-3 months after stopping, with odds ratios reaching 2.51 during this window 4
- Absolute stroke rates: Approximately 15.42 per 100 patient-years after discontinuation versus 0.26 per 100 patient-years in those who continue 5
The most recent and robust evidence comes from a 2024 Danish nationwide cohort study of 8,119 patients with AF who had already suffered an ischemic stroke 1. Despite being on secondary prevention with anticoagulation, the crude cumulative incidence of recurrent stroke at 1 year was 4.3%. Critically, patients who discontinued anticoagulation had more than double the risk of recurrent stroke (adjusted OR 2.13) compared to those who continued treatment 1.
Risk Applies to All Anticoagulants
The increased stroke risk after discontinuation is similar across anticoagulant types 2:
- Warfarin discontinuation: OR 1.83-2.38 for stroke
- DOAC discontinuation: OR 3.37-4.59 for stroke (potentially higher due to shorter half-lives)
- Individual DOACs show comparable risks: apixaban (OR 1.98), dabigatran (OR 1.98), rivaroxaban (OR 1.87), edoxaban (OR 1.38) 4
Additional Consequences Beyond Stroke
Discontinuation increases not just stroke risk, but overall cardiovascular morbidity and mortality 3:
- All-cause mortality: 1.62-fold increase
- Myocardial infarction: 1.85-fold increase
- Major adverse cardiac and cerebrovascular events: 60.82 per 100 patient-years after discontinuation versus 0.36 in those continuing 5
Baseline Stroke Risk Context
To understand the impact of discontinuation, consider that untreated AF carries a baseline stroke risk of approximately 5% per year, increasing with age from 1.5% in patients 50-59 years old to 23.5% in those 80-89 years old 6. Anticoagulation with warfarin reduces this risk by 61% compared to placebo 7, 8. When anticoagulation is stopped, patients essentially return to—or exceed—their baseline untreated stroke risk 9, 10.
Clinical Implications
The decision to discontinue anticoagulation should never be taken lightly. Current guidelines universally recommend anticoagulation for patients with AF and prior stroke/TIA (CHA₂DS₂-VASc score ≥2), with Class I, Level A evidence 7. The 2021 AHA/ASA guidelines emphasize that anticoagulation is recommended regardless of whether AF is paroxysmal, persistent, or permanent 7.
When Temporary Interruption is Necessary
For patients requiring procedures, bridging strategies should be considered for high-risk patients (stroke/TIA within 3 months, CHA₂DS₂-VASc score 5-6, mechanical valves) 9. Even brief interruptions >3 days carry substantial risk, with rates of ischemic stroke/systemic embolism of 15.42 per 100 patient-years during the interruption period 5.
Common Pitfalls
- Underestimating risk in "stable" patients: Even patients who have been event-free on anticoagulation face dramatically increased risk upon discontinuation
- Assuming paroxysmal AF is lower risk: Stroke risk and the consequences of discontinuation are similar across all AF patterns 7
- Discontinuing due to minor bleeding: The stroke risk from discontinuation typically far exceeds the bleeding risk from continuation, except in cases of life-threatening hemorrhage 11
Bottom line: Anticoagulation discontinuation in AF patients should be avoided whenever possible, as it results in a 2-3 fold increase in stroke risk that peaks within 2-3 months and persists as long as the patient remains off therapy. When discontinuation is absolutely necessary, resumption should occur as soon as medically feasible 3, 5.